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Introduction: Improvement in coronary heart disease prevention and treatment, as well as
availability of coronary care facilities, is important for the reduction of acute coronary
syndrome (ACS) incidence. Centralized acute coronary care system is crucial to provide
optimal hospitalization and management algorithm for ACS patients.
Aim: The aim of the current report was to assess the annual incidence of ACS and the quality
of acute coronary care in Latvia.
Methods: The Data from The Latvian Registry of Acute Coronary Syndromes were analyzed
covering the time period from 2005 to 2010.
Results: Since the year 2005 the annual incidence of hospitalization due to ACS decreased
signiﬁcantly in Latvia. The annual incidence of non-ST-elevation ACS (NSTE-ACS) decreased
from 8019 to 4613 in absolute numbers based on the registry data during six years.
Improvement in the use of guidelines based therapy and early invasive strategy in ACS
patients was observed. Increase in primary percutaneous coronary intervention was
achieved from 7.9% in 2005 to 57.0% in 2010, contributing to reduction in the proportion
of STEMI patients without any reperfusion (from 45% in 2005 to 21% in 2010).
Conclusions: The annual incidence of hospitalized ACS, especially NSTE-ACS, decreased and
guidelines based management of ACS improved from 2005 to 2010 in Latvia.
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Continuous physician education, development of clinical
guidelines and recommendations, and their implementation
in practice, and the availability of diagnostic coronary
angiography and coronary intervention are measures that
are crucial in reduction of acute coronary syndrome (ACS)
morbidity. Moreover, centralized emergency medical services
(EMS) are vital in order to promote optimal algorithm of
hospitalization or the transfer to specialized hospitals to
provide best possible care for patients with ACS. ACS registry,
covering the whole country, both represents consequences of
primary and secondary prevention by decreasing the inci-
dence of ACS and serves as a measure for quality of care in
patients hospitalized with ACS.
The new member states of the European Union have high
cardiovascular disease rates, which is in marked contrast to
that in the most economically stable European countries
where declines in cardiovascular mortality rates have been
experienced over the last 30 years [1]. Coronary heart disease is
the leading cause of death in Latvia [2]. ACS is the most
common reason for cardiac hospitalization tied with high
mortality risk and requiring advanced care [3].
Early coronary angiography and revascularization are a
cornerstone in contemporary management of ACS, however;
improvement of regionalized systems is of no less importance
[4–7]. In patients with ST-segment elevation myocardial
infarction (STEMI) primary percutaneous coronary interven-
tion (P-PCI) in a time saving manner is the preferred strategy.
Thus empowering EMS and implementation of regional
guidelines were the ﬁrst steps in forming an effective STEMI
regional network providing majority of patients with P-PCI
and others with ﬁbrinolysis (FL) and facilitated PCI. Addition-
ally early invasive strategy in non-ST-elevation ACS (NSTE-
ACS) patients reduces refractory ischemia and improves
survival in intermediate and high risk NSTE-ACS patients
[5,8–14].
Assessment of quality has become an integral part of care,
usually by the evaluation of implementation of clinical
guidelines in real life practice. Thus, to analyze acute coronary
care quality in Latvia, the ongoing national registry of ACS was
introduced in the year 2005. The aim of this report was to
analyze the annual incidence of ACS and quality of care in ACS
patients during the time period of 5 years from 2005 to 2010 in
Latvia.
Methods
The Latvian Registry of Acute Coronary Syndromes is an
ongoing, prospective, multi-center, observational registry
designed to examine current epidemiology, in-hospital man-
agement and the outcome of patients with ACS in Latvia. A
total of 34 hospitals participated in the registry during the
study period from the 1st of January 2005 to the 31st of
December 2010. To minimize selection bias all consecutive
patients with a suspected diagnosis of acute coronary
syndrome were included, regardless of the treatment strategy
or outcome. Data concerning baseline demographic andclinical characteristics, relevant laboratory results, pharmaco-
therapy during hospital stay, and adverse cardiovascular
outcomes were recorded on a standardized electronic web
page-based case report form. Data were collected in a central
electronic database. Standardized deﬁnitions were used for
adverse events and ﬁnal diagnosis [15,16]. For the purpose of
the present analysis patients were classiﬁed as NSTE-ACS and
STEMI. The occurrence of other ischemic or bleeding events
was not analyzed. We analyzed adherence to therapies
recommended by guidelines, early interventional strategy,
coronary risk factors, patient history data and in-hospital
mortality. Hypercholesterolemia was deﬁned as total blood
cholesterol above 4.5 mmol/l, and arterial hypertension was
deﬁned as blood pressure 140/90 mmHg or above without
medications or the use of antihypertensive agents in history.
Reperfusion strategy was documented in STEMI patients.
STEMI patients eligible for reperfusion therapy were deﬁned as
patients hospitalized within 12 h from symptom onset.
Reperfusion strategy, P-PCI or ﬁbrinolysis (FT) was analyzed
in this patient subgroup.
The data of Central Statistical Bureau Database of Latvia
were used for the calculation of annual incidence of STEMI and
NSTE-ACS per million population. This was calculated for each
year using the total population for each year given by Central
Statistical Bureau Database of Latvia.
Statistical analyses
Statistical analyses were performed with SPSS software
(version 17.0, Chicago, Illinois, USA). Continuous values are
expressed as mean  SD. Categorical variables are presented
as percentages. Categorical variables were compared with Chi-
square test and continuous variables with ANOVA. P values
under 0.05 were considered as statistically signiﬁcant.
Results
Since the year 2005 the total number of ACS patients, both
STEMI and NSTE-ACS, hospitalized across Latvia as assessed
by the current registry decreased (Tables 1 and 2). The number
of STEMI and NSTE-ACS calculated per million population
decreased over years (Fig. 1). More prominent decrease was
observed among NSTE-ACS patients. The total number of
patients hospitalized with NSTE-ACS decreased almost two-
fold based on registry data. Early interventional strategy and
better adherence to guidelines recommended therapies
improved in NSTE-ACS patients over years (Table 1). Reduction
in intra-hospital mortality was observed in 2010 in NSTE-ACS
patients (Table 1).
The use of P-PCI in Latvia signiﬁcantly increased from
7.9% in 2005 to 57.0% in 2010 along with the use of
antiplatelet therapy (Tables 2 and 3). The most prominent
increase was observed in the use of clopidogrel – 30.2% in
2005 compared with 94.6% in 2010. Supplementary with
increase in PCI rates, the use of GP IIb/IIIa inhibitors
increased from 10.7% in 2005 to 46.8% in 2010. Proportion
of STEMI patients without any reperfusion decreased from
46.3% in 2005 to 20.8% in 2010 (Fig. 2). However, only a slight
decrease in intra-hospital mortality in STEMI patients over
Table 1 – Characteristics of NSTE-ACS patients.
2005 2006 2007 2008 2009 2010 p-Value
Number of patients, n 8019 6437 5573 6184 4437 4613
Cardiogenic shock, n (%) 80 (1.0) 131 (2.0) 122 (2.2) 153 (2.5) 117 (2.6) 65 (1.4) <0.0001
Intra-hospital death, n (%) 269 (3.4) 258 (4.0) 284 (5.1) 348 (5.6) 230 (5.2) 166 (3.6) <0.0001
Age  SD, years 68.32  11.29 68.59  11.26 68.67  11.41 69.73  11.40 69.25  11.69 68.84  11.61 <0.0001
Arterial hypertension, n (%) 5033 (62.8) 4345 (67.5) 3753 (67.3) 4254 (68.8) 2820 (63.6) 2911 (63.1) <0.0001
Diabetes mellitus, n (%) 1424 (17.8) 1145 (17.8) 1001 (18.0) 1136 (18.4) 807 (18.2) 918 (19.9) 0.051
Hypercholesterolemia
(TC >4.5 mmol/l), n (%)
3905 (48.8) 2845 (44.2) 2927 (52.5) 3243 (52.4) 2247 (50.6) 2094 (45.4) < 0.0001
Previous myocardial
infarction, n (%)
3170 (39.5) 2404 (37.3) 2079 (37.3) 2304 (37.3) 1604 (36.2) 1562 (33.9) <0.0001
Previous stroke, n (%) 519 (6.5) 415 (6.4) 363 (6.5) 407 (6.6) 275 (6.2) 269 (5.8) 0.651
Atrial ﬁbrillation, n (%) 1434 (17.9) 1177 (18.3) 1005 (18.0) 1151 (18.6) 718 (16.2) 638 (13.8) <0.0001
PCI at index
hospitalization, n (%)
507 (6.3) 663 (10.3) 621 (11.1) 719 (11.6) 1016 (22.9) 1295 (28.1) <0.0001
Coronary angiography
at index hospitalization,
n (%)
– – 859 (15.4) 1031 (16.7) 1391 (31.4) 1699 (36.8) <0.0001
Aspirin, n (%) 7250 (90.4) 5817 (90.4) 5004 (89.8) 5583 (90.3) 3988 (89.9) 4056 (87.9) <0.0001
Thienopyridines, n (%) 1384 (17.3) 2249 (34.9) 2804 (50.3) 3232 (52.3) 2744 (61.8) 3406 (73.8) <0.0001
ACE-inhibitors, n (%) 5802 (72.4) 4877 (75.8) 4031 (72.3) 4473 (72.3) 3060 (69.0) 3027 (65.6) <0.0001
Beta-blockers, n (%) 6740 (84.1) 5405 (84.0) 4635 (83.2) 5133 (83.0) 3697 (83.3) 3866 (83.8) 0.471
Statins, n (%) 5316 (66.3) 5069 (78.7) 4557 (81.8) 5052 (81.7) 3781 (85.2) 3941 (85.4) <0.0001
GP IIb/IIIa inhibitors, n (%) 255 (3.2) 409 (6.4) 486 (8.7) 517 (8.4) 429 (9.7) 352 (7.6) <0.0001
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patients without any reperfusion remained very high
(Table 4).
Absolute numbers of transferred patients from community
hospitals to PCI centers increased over years (Fig. 3).
Discussion
The main challenges in the last twenty years have been the
reduction of incidence of cardiovascular disease and theTable 2 – Characteristics of STEMI patients.
2005 2006 200
Number of patients, n 1815 1823 1499 
Cardiogenic shock, n (%) 156 (8.6) 198 (10.9) 123 (8.2
Intra hospital death, n (%) 312 (17.4) 288 (15.8) 208 (13
Age  SD, years 67.49  12.07 66.85  12.33 65.81 
Arterial hypertension, n (%) 872 (48.0) 981 (53.8) 755 (50
Diabetes mellitus, n (%) 298 (16.4) 324 (17.8) 235 (15
Hypercholesterolemia,
n (%), TC >4.5 mmol/l
907 (50.2) 966 (53.0) 911 (60
Previous myocardial
infarction, n (%)
422 (23.3) 400 (22.0) 305 (20
Previous stroke, n (%) 126 (6.9) 149 (8.2) 113 (7.5
Atrial ﬁbrillation, n (%) 222 (12.2) 221 (12.1) 173 (11
PCI at index
hospitalization, n (%)
242 (13.3) 400 (22.0) 506 (33
Coronary angiography at
index hospitalization, n (%)
– – 523 (34
Aspirin, n (%) 1703 (93.8) 1712 (93.9) 1412 (94
Thienopyridines, n (%) 548 (30.2) 1153 (63.2) 1232 (82
ACE-inhibitors, n (%) 1222 (67.3) 1269 (69.6) 997 (66
Beta-blockers, n (%) 1523 (83.9) 1490 (81.7) 1276 (85
Statins, n (%) 1456 (80.2) 1566 (85.9) 1318 (87
GP IIb/IIIa inhibitors, n (%) 195 (10.7) 314 (17.2) 452 (30reduction of cardiovascular mortality. For this purpose
continuous education of cardiologists, emergency care spe-
cialists and general practitioners has been implemented.
Multiple, regular educational seminars and congresses were
held during this time period across the country, and local
guidelines on acute coronary care were developed in 2006 and
updated in 2011. Local recommendations on stable coronary
disease and coronary prevention were developed and imple-
mented in real life practice. Besides availability of coronary
care services such as diagnostic coronary angiography,
coronary intervention, exercise test and non-invasive cardiac7 2008 2009 2010 p-Value
1703 1530 1542
) 158 (9.3) 198 (12.9) 157 (10.2) <0.0001
.9) 270 (15.9) 219 (14.3) 206 (13.4) 0.01
 12.48 67.16  12.36 65.56  13.15 65.90  12.58 <0.0001
.4) 898 (52.7) 733 (47.9) 712 (46.2) <0.0001
.7) 266 (15.6) 219 (14.3) 205 (13.3) 0.008
.8) 1007 (59.1) 959 (62.7) 959 (62.2) < 0.0001
.3) 337 (19.8) 273 (17.8) 243 (15.8) <0.0001
) 137 (8.0) 107 (7.0) 88 (5.7) 0.077
.5) 209 (12.3) 149 (9.7) 153 (9.9) 0.051
.8) 542 (31.8) 890 (58.2) 1038 (67.3) <0.0001
.9) 582 (34.2) 948 (62.0) 1076 (69.8) <0.0001
.2) 1593 (93.5) 1465 (95.8) 1475 (95.7) 0.013
.2) 1398 (82.1) 1380 (90.2) 1458 (94.6) <0.0001
.5) 1130 (66.4) 1021 (66.7) 962 (62.4) 0.001
.1) 1430 (84.0) 1298 (84.8) 1272 (82.5) 0.061
.9) 1478 (86.8) 1374 (89.8) 1369 (88.8) <0.0001
.2) 478 (28.1) 665 (43.5) 721 (46.8) <0.0001
Table 4 – In-hospital mortality in STEMI patients hospitalized within 12 h after symptom onset.
Year STEMI patients without
cardiogenic shock
STEMI patients with
cardiogenic shock
All STEMI patients
P-PCI Fibrinolysis Without
reperfusion
P-PCI Fibrinolysis Without
reperfusion
P-PCI Fibrinolysis Without
reperfusion
2005, % (n) 1.2% (1) 10.3% (57) 17.0% (89) 17.6% (3) 41.7% (15) 81.0% (51) 4.0% (4) 12.2% (72) 23.9% (140)
2006, % (n) 0.5% (1) 6.6% (33) 17.2% (89) 33.3% (7) 55.6% (25) 75.9% (66) 3.7% (8) 10.7% (58) 25.6% (155)
2007, % (n) 0.3% (1) 9.3% (35) 16.5% (53) 50.0% (18) 26.3% (5) 72.1% (31) 5.9% (19) 10.1% (40) 23.1% (84)
2008, % (n) 0.3% (1) 10.9% (50) 18.6% (66) 47.4% (18) 44.8% (13) 75.9% (41) 5.6% (19) 12.9% (63) 26.2% (107)
2009, % (n) 2.6% (12) 9.4% (24) 13.6% (32) 54.5% (36) 34.0% (16) 84.9% (45) 9.2% (48) 13.2% (40) 26.7% (77)
2010, % (n) 3.1% (18) 11.9% (26) 19.3% (38) 58.3% (35) 43.8% (14) 76.9% (30) 8.2% (53) 16.0% (40) 28.8% (68)
Table 3 – Characteristics of STEMI patients hospitalized within 12 hours after symptom onset.
2005 2006 2007 2008 2009 2010 p-Value
Number of patients, n 1290 1365 1082 1236 1112 1132
Cardiogenic shock, n (%) 117 (9.1) 153 (11.2) 98 (9.1) 121 (9.8) 166 (14.9) 131 (11.6) <0.0001
Intra-hospital death, n (%) 216 (16.7) 222 (16.3) 143 (13.2) 189 (15.3) 165 (14.8) 161 (14.2) 0.135
Age  SD, years 67.20  11.78 66.61  12.58 65.79  12.36 67.08  12.19 65.89  13.47 66.20  12.60 0.018
Reperfusion
Fibrinolysis, n (%) 591 (45.8) 541 (39.7) 396 (36.6) 489 (39.6) 302 (27.2) 250 (27.2) <0.0001
Primary PCI, n (%) 102 (7.9) 215 (15.8) 322 (29.8) 339 (27.4) 522 (46.9) 645 (57.0) <0.0001
Without reperfusion, n (%) 597 (46.3) 605 (44.3) 364 (33.6) 408 (33.0) 288 (25.9) 236 (20.8) <0.0001
PCI at index
hospitalization, n (%)
184 (14.3) 313 (23.0) 387 (35.8) 420 (34.0) 650 (58.5) 738 (65.2) <0.0001
Aspirin, n (%) 1222 (94.7) 1280 (93.8) 1029 (95.1) 1170 (94.7) 1061 (95.4) 1077 (95.1) 0.514
Thienopyridines, n (%) 415 (32.2) 892 (65.3) 905 (83.6) 1035 (83.7) 1011 (90.9) 1064 (94.0) <0.0001
ACE-inhibitors, n (%) 867 (67.2) 939 (68.8) 728 (67.3) 827 (66.9) 729 (65.6) 684 (60.4) <0.0001
Beta-blockers, n (%) 1092 (84.7) 1116 (81.8) 928 (85.8) 1050 (85.0) 934 (84.0) 920 (81.3) 0.013
Statins, n (%) 1048 (81.2) 1173 (86.0) 957 (88.4) 1083 (87.6) 1002 (90.1) 998 (88.2) <0.0001
GP IIb/IIIa inhibitors, n (%) 144 (11.2) 253 (18.5) 355 (32.8) 372 (30.1) 491 (44.2) 568 (50.2) <0.0001
Fig. 1 – Annual incidence of STEMI and NSTE-ACS according to ACS registry calculated per million inhabitants of Latvia.
*According to Central Statistical Bureau Database of Latvia resident population at the beginning of the following years were
as follows: 2,306,434 in 2005; 2,294,590 in 2006, 2,281,305 in 2007; 2,270,894 in 2008; 2,261,294 in 2009 and 2,248,374 in 2010.
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Fig. 2 – Reperfusion in STEMI patients hospitalized within 12 h after symptom onset in Latvia.
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increase in diagnostic coronary angiograms is from 2258 in
2005 to 5643 in 2010 per million population, with respective
increase in PCI from 1169 to 2859 per million population in
Latvia. Increase in coronary interventions was achieved with
the education of new interventional cardiologists and the
opening of new catheterization laboratories and intervention-
al centers. Since 2003 two university hospitals have provided
interventional coronary care in Riga. Two additional interven-
tional centers in 2007 were opened in two other cities
(Daugavpils and Liepaja), both situated more than 200 km
from the capital Riga.
Evaluation of intra-hospital acute coronary care conﬁrmed
better adherence to evidence-based guidelines. Not only more
frequent administration of recommended drugs but also more
common use of diagnostic coronary angiograms followed by
PCI was observed. Increase in the use of interventional
strategy in the management of both NSTE-ACS and STEMI
was the result of not only physician education and availability
of interventional centers, but also restructuring and centrali-
zation of EMS in Latvia.
Admission to higher-volume hospitals was associated with
a reduction in mortality for acute myocardial infarction
according to the literature [17]; thus number of small capacity
community hospitals was restructured to serve as ambulatory
clinics and total number of hospitals providing acute coronary
care was reduced from 35 in 2005 to 18 in 2010. Reduction of
low capacity hospitals in acute coronary care network provides
the possibility for ACS patients to be hospitalized to higher
volume centers, thus expecting better quality of care and
prognosis.
Majority of patients with ACS arrive at the hospital via
EMS ambulance in Latvia, thus EMS plays a crucial role in the
distribution of ACS patients among hospitals. EMS was
restructured and served as a centralized system ensuringhospitalization of ACS patients to tertiary centers only since
2009–2010. STEMI network algorithms were adapted from
European Society of Cardiology recommendations and
adjusted for local situation, published in local guidelines
and implemented in real life practice [4–6]. Thus, more
STEMI patients were routed directly to interventional
centers or transferred on the next day after FL if more than
2-h delay from the ﬁrst medical contact to balloon was
expected. As a result signiﬁcant increase in the use of P-PCI
from 7.9% in 2005 to 57.0% in 2010 and decrease in STEMI
patients without any reperfusion were observed (Table 3,
Fig. 2).
P-PCI is preferable and it is the leading reperfusion strategy
for STEMI in most European countries [18]; however, in the
‘‘real world’’ choice of a management strategy is often
governed by the facilities available in the hospital where
patients initially present. Only four hospitals in Latvia (two
hospitals in Riga) have PCI facilities and 24-h/7-day interven-
tional access is available only in Riga (since 2007 one hospital
and since February 2010 two hospitals).
Positive associations between interventional strategy and
improved outcomes in patients with ACS argue for the routing
of those patients from community hospitals to hospitals with
access to catheterization laboratory [18–24]. Partly, problems
were settled with better organization of networks among the
EMS and P-PCI hospitals. This resulted in signiﬁcant increase
in absolute numbers of transferred patients from community
hospitals to PCI centers over years (Fig. 2). These patients were
routed to Latvian Centre of Cardiology mainly for coronary
intervention. In all, 74.5% (n = 190) from transferred NSTE-ACS
and 90.7% (n = 233) from transferred STEMI patients under-
went interventional treatment at index hospitalization in year
2010. Coronary angiography was performed in 91.0% (n = 232)
transferred NSTE-ACS and in 95.7% (n = 246) transferred STEMI
patients in 2010.
Fig. 3 – Absolute number of transferred patients from community hospitals to Latvian Centre of Cardiology.
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therapies only slight decrease in intra-hospital mortality
was achieved. Very high intra-hospital death rates were
observed in patient subgroup without any reperfusion
(Table 4), contributing to high total intra-hospital mortality
rates in STEMI patients. STEMI patients in cardiogenic shock
had high in-hospital mortality, especially those without
reperfusion ranging from 72 to 85% in this subset. Reperfused
patients in cardiogenic shock had almost halved in-hospital
morality rates compared to patients without reperfusion
therapy. Patients in cardiogenic shock in P-PCI subgroup
had worsened outcomes compared to the ﬁbrinolysis sub-
group evaluating mortality rate alone. However, rates of P-PCI
especially in last years have increased. P-PCI was widely
applied in critically ill, resuscitated cardiogenic shock patients,
and even in those with serious accompanying diseases
possibly regarded as contraindication for FL.
In-hospital mortality rates in STEMI patients undergoing P-
PCI in respect to percent from treated patients increased over
years. However, in the time period from 2005 to 2007 P-PCI was
performed in selected patients, but since 2008 in Latvian
Centre of Cardiology and since 2009 in Riga Eastern Clinical
University hospital, P-PCI policy for all-comers was initiated.
Thus, critically ill patients as well as aging patients and
patients with contraindications for other treatment options
received P-PCI, which led to relatively higher in-hospital
mortality rates in respect to percent from treated patients in
this subset. Nonetheless, the total in-hospital mortality in
STEMI patients (Tables 2 and 3) was decreasing over years;
thus incremental beneﬁt of more aggressive reperfusion in
combination with better use of drug therapy could serve as an
explanation.
A higher proportion of STEMI patients were hospitalized in
cardiogenic shock (8.6% in 2005 versus 10.2% in 2010) and a
higher proportion of patients in the age group above 80 years
(15.7% in 2005 vs. 18.4% in 2010 from all ACS patients),
subgroup of patients with worsened prognosis. This registry islimited only with in-hospital data, which in terms of mortality
is not the best reﬂection of quality of care, while guidelines
based management, P-PCI in STEMI and early interventional
strategy in NSTE-ACS are believed to reduce serious adverse
cardiac events including mortality in longer term [6,7,10–14].
In NSTE-ACS patients intra-hospital death rate decreased
in 2010 compared with that in 2006–2009, possibly reﬂecting
better adherence to guidelines recommended therapy and
intensiﬁed patient transfer from community hospitals to
interventional centers.
Emergency care specialists, cardiologists, and general
practitioners are being continuously educated; however,
acceptable reperfusion rates in STEMI patients were not
achieved. Insufﬁcient amount of trained and experienced
interventional cardiologists outside capital city is the main
barrier for wider P-PCI implementation across the country.
Until now some physicians and EMS specialists have a
conservative attitude toward early interventional strategy in
STEMI as well as in NSTE-ACS. Thus, the development of ACS
teams at community hospitals able to identify STEMI patients
accurately as well as high and immediate risk NSTE-ACS
eligible for P-PCI or early interventional treatment, correctly
administer preferred initial medications, and rapidly transfer
patients directly to the specialized center is still needed.
Conclusions
The annual incidence of ACS, especially NSTE-ACS, as
assessed by acute coronary syndrome registry decreased over
the years. Better adherence to guidelines recommended
therapy and more often the use of interventional strategy in
the analyzed time period from year to year was observed. A
nationwide P-PCI strategy for STEMI was introduced in the
previous years and subsequently the rate of P-PCI increased
seven-fold since 2005. Nevertheless, still a signiﬁcant number
of STEMI patients did not receive any reperfusion therapy
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 3 2 5 – e 3 3 2 e331resulting in high mortality rates in this subgroup. In NSTE-ACS
intra-hospital death rate decreased and early interventional
strategy increased from year to year in the analyzed time
period.
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